Further, TP53 mutations have been found to correlate with increased immune infiltration and to associate with remarkable clinical benefit to anti-PD-1 therapy in lung adenocarcinoma and acute myeloid leukaemia [42]. The gene discussed is TP53; the disease is lung adenocarcinoma.